



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Marian L. Kruzel

Serial No.: 10/023,096

Filed: 12/18/01

Title: TREATING COMPOSITIONS
WITH LACTOFERRIN

§
§
§
§
§
§
§
§
§

Group Art Unit: 1647

Examiner:

Attorney docket
No.: FDI004

RECEIVED
TPO/SEI/ER 1500/2300
02 MAR 21 AM 9:49

Transmittal

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

In the specification:


Replace pages 27-33 with new pages 27-36. Change the page numbers for pages 34, 35 and 36 to -- 37 --, -- 38-- and --39 --, respectively.

The content of the sequence in computer readable form is identical to that written on pages 27 to 33 of the application as filed as well as new pages 28-36.

A new Declaration is enclosed correctly the typos in the original Declaration.

A Information Disclosure Citation is enclosed.

Respectfully submitted,



Kurt S. Myers
Attorney for Applicants
Reg. No.. 20,244
7634 Braesdale
Houston, Texas 77071
(713) 774-7152

CERTIFICATE OF MAILING

I hereby certify that this **Transmittal** is being hand carried by Federal Express to the U.S. Patent Office.



Kurt S. Myers



COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

APR 11 2002

Page 1 of 2

UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/023,096	12/18/2001	Marian L. Kruzel	FDI004

Kurt S. Myers
7634 Braesdale
Houston, TX 77071

CONFIRMATION NO. 3500

FORMALITIES LETTER



OC000000007428955

Date Mailed: 02/06/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

M. Manual

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 3 - OFFICE COPY